Contents
A prostate-specific antigen, or PSA, blood test measures a protein produced by cells in the prostate gland. Healthcare providers use PSA testing to support prostate cancer screening, investigate certain prostate or urinary concerns, and monitor people who have already been treated for prostate cancer.
Understanding PSA levels is not as simple as comparing one number with a universal cutoff. A PSA result may be influenced by age, prostate size, benign prostatic hyperplasia, inflammation, infection, ejaculation, vigorous cycling, recent prostate procedures, medications, and individual prostate cancer risk.
A high PSA level does not prove that prostate cancer is present. A low PSA level also cannot completely rule it out. The most useful interpretation considers your current result, previous PSA levels, symptoms, medications, family history, overall health, and the reason the test was ordered.
Ulta Lab Tests provides direct access to several PSA and prostate health blood tests. Laboratory testing supplies objective health information, but it does not replace an examination, diagnosis, or personalized medical recommendations from a qualified healthcare provider.

PSA stands for prostate-specific antigen. It is a protein made by both normal and abnormal cells within the prostate. Most PSA enters semen, but a small amount normally enters the bloodstream.
A PSA blood test reports the concentration of this protein in nanograms per milliliter, written as ng/mL. PSA testing may be used for several purposes:
PSA is better understood as a prostate activity marker than as a cancer-specific marker. Prostate cancer can raise PSA, but several noncancerous conditions can also increase it.
Direct answer: There is no universally normal or abnormal PSA level. In general, concern tends to increase as PSA rises, but results must be interpreted in the context of age, risk factors, prostate size, medications, symptoms, and earlier PSA measurements.
A cutoff of 4.0 ng/mL was historically used to identify an elevated PSA. Some clinicians use lower thresholds for younger or higher-risk patients and higher thresholds for selected older patients. A value below 4.0 ng/mL does not guarantee that prostate cancer is absent, and a result above 4.0 ng/mL does not establish that cancer is present.
| PSA Result | General Context | Possible Next Discussion |
|---|---|---|
| Below 2.5 ng/mL | Often associated with a lower level of immediate concern during screening, but it does not rule out prostate cancer. | Determine an appropriate future screening interval based on age, health, and risk. |
| 2.5–4.0 ng/mL | May be considered appropriate for some people but elevated for others, especially at a younger age or with significant risk factors. | Review previous PSA levels, family history, medications, symptoms, and the appropriate screening interval. |
| 4.0–10.0 ng/mL | Often called the borderline or gray range. Prostate cancer is one possible cause, but benign enlargement and inflammation are common alternatives. | Repeat PSA, clinical evaluation, percent-free PSA, risk assessment, or imaging may be considered. |
| Above 10.0 ng/mL | Associated with greater concern and generally warrants timely clinical evaluation. | Confirm the result and discuss additional evaluation with a healthcare provider. |
| Any unexpected increase | May reflect biological variation, temporary prostate irritation, infection, medication effects, or a meaningful change. | Review test preparation and consider repeat testing before assuming a diagnosis. |
The American Cancer Society describes PSA between 4 and 10 ng/mL as a commonly recognized borderline range. Even within this range, PSA is not diagnostic, and some detected cancers may be low grade.
Direct answer: There is no single PSA value that can be labeled dangerous for everyone.
A PSA above 10 ng/mL usually creates more concern than a PSA of 4 or 5 ng/mL, but the number alone cannot reveal the cause, cancer grade, cancer stage, or whether immediate treatment is necessary. Clinically significant prostate cancer can also occasionally be present when PSA is below traditional thresholds.
An unexpectedly elevated result should be treated as a signal for appropriate follow-up, not as a diagnosis.
Healthcare providers may consider:
Current prostate cancer screening guidance emphasizes shared decision-making rather than applying one PSA cutoff to every patient.
PSA often increases with age because the prostate commonly grows larger over time. However, fixed age-based normal ranges can provide false reassurance or create unnecessary anxiety.
Age is most useful when combined with a person’s health, risk factors, expected longevity, baseline PSA, and preferences.
| Age or Risk Group | Screening Discussion |
|---|---|
| Around age 40 | The American Cancer Society recommends a discussion for those at especially high risk, including men with more than one first-degree relative diagnosed at an early age. |
| Around age 45 | A discussion is recommended for Black men and men with a father or brother diagnosed before age 65. |
| Around age 50 | Average-risk men expected to live at least 10 more years may discuss the potential benefits and harms of screening. |
| Ages 55–69 | The U.S. Preventive Services Task Force recommends an individual decision based on health, preferences, and potential benefits and harms. |
| Age 70 and older | The U.S. Preventive Services Task Force recommends against routine PSA screening. Symptom evaluation and PSA monitoring after a previous diagnosis are separate clinical situations. |
Professional organizations do not use identical starting ages or screening intervals. An individualized conversation is therefore more appropriate than assuming everyone should begin and stop PSA testing at the same age.
An elevated PSA may result from cancerous or noncancerous causes.
Benign prostatic hyperplasia, or BPH, is noncancerous enlargement of the prostate. As the amount of prostate tissue increases, PSA may rise. BPH can also cause a weak urine stream, difficulty starting urination, frequent urination, and nighttime urination.
Prostatitis is inflammation of the prostate. It may be associated with infection, pelvic discomfort, painful urination, fever, or urinary changes. Prostate inflammation can sometimes cause a substantial temporary PSA increase.
A urinary tract infection may affect PSA interpretation, especially when it causes prostate or urinary inflammation. Testing may need to be postponed until the infection has been evaluated and resolved.
Ejaculation may temporarily raise PSA. MedlinePlus advises avoiding sex or masturbation for at least 24 hours before testing, while the National Cancer Institute notes that activities known to raise PSA are often avoided for approximately two days. Follow the preparation instructions for the specific test ordered.
Vigorous activities that place pressure on the prostate, particularly cycling, can temporarily affect PSA in some people. Avoiding these activities for approximately 48 hours before collection may reduce the risk of a misleading result.
A prostate biopsy, urinary procedure, catheterization, or other manipulation of the prostate may raise PSA. A biopsy-related increase can persist for several weeks. Ask a healthcare provider how long you should wait before testing.
Finasteride and dutasteride, which may be prescribed for BPH or hair loss, can lower measured PSA. Other medications and therapies may also affect interpretation. Never stop a medication to prepare for a PSA test unless the prescribing healthcare provider instructs you to do so.
Early prostate cancer often causes no symptoms. When urinary symptoms occur, they are frequently caused by noncancerous conditions such as BPH, prostatitis, or a urinary infection.
| Symptom or Risk Factor | What It May Suggest | Tests That May Provide Information |
|---|---|---|
| Increasing age without symptoms | Age-related prostate changes or a need to discuss screening | PSA Total Test |
| Black ancestry or a strong family history | Increased prostate cancer risk | PSA Total Test, followed by clinician-directed risk assessment |
| Weak urine stream or difficulty starting | BPH, urinary obstruction, inflammation, or another urinary condition | PSA Total Test, Urinalysis Complete Test, and clinical evaluation |
| Frequent or nighttime urination | BPH, diabetes, urinary infection, bladder problems, or another cause | PSA Total Test, Urinalysis Complete Test, and Culture, Urine, Routine Test when appropriate |
| Burning urination, fever, chills, or pelvic pain | Urinary infection or prostatitis | Urinalysis Complete Test, Culture, Urine, Routine Test, Complete Blood Count with Differential and Platelets, and clinical evaluation |
| Unexpectedly elevated PSA without symptoms | Temporary variation, BPH, inflammation, medication effects, or prostate cancer risk | Repeat PSA Total Test and, in selected cases, the PSA Free and Total Test |
| History of prostate cancer treatment | A need for treatment-response or recurrence monitoring | Post-Prostatectomy PSA Test or another clinician-directed assay |
| Blood in the urine, inability to urinate, severe pain, unexplained weight loss, or persistent bone pain | Requires prompt medical evaluation | Do not rely on direct-access PSA testing alone |
Safety note: Seek prompt medical care for urinary retention, visible blood in the urine, fever with urinary symptoms, severe pelvic or back pain, weakness, unexplained weight loss, or other sudden or concerning symptoms.
PSA testing can show how much prostate-specific antigen is circulating in the blood. Repeated measurements may also show whether PSA is stable, fluctuating, rising, or falling.
PSA testing cannot determine by itself:
When an asymptomatic person has a newly elevated PSA, a clinician may recommend repeating the test in approximately six to eight weeks to confirm the finding. Timing may be adjusted when infection, inflammation, recent procedures, or other temporary influences are suspected.
Trends can be useful, but the speed of PSA change should not be interpreted in isolation. Age, total PSA, free PSA, previous results, family history, prostate examination, imaging, and other risk information may also be needed.

| Lab Test or Biomarker | What It Measures | Why It May Be Relevant | General Interpretation | Important Limitations |
|---|---|---|---|---|
| PSA Total Test | Total circulating PSA, including free and protein-bound PSA | A common first-line PSA measurement for screening and monitoring | Higher levels may be associated with BPH, prostatitis, infection, prostate irritation, or cancer. | Cannot diagnose prostate cancer or identify the cause of an elevation. |
| PSA Total Test with 2.5 ng/mL Cutoff | The total PSA biomarker reported using a lower decision threshold | May help identify results that warrant closer review in selected patients | A result above 2.5 ng/mL does not mean cancer is present, but it may affect follow-up discussions. | It is not inherently more accurate than another total PSA test and may increase false-positive follow-up. |
| PSA Free and Total Test | Total PSA, free PSA, and the percentage of PSA that circulates freely | May provide additional context when total PSA is elevated or within a borderline range | A lower percent-free PSA is generally associated with greater prostate cancer concern, while a higher percentage may be more consistent with benign causes. | Does not diagnose cancer or eliminate the need for clinical risk assessment. |
| Repeat PSA Total Test | A second total PSA measurement | Helps determine whether an unexpected elevation persists | A return toward baseline may suggest temporary variation, while a persistent elevation warrants review. | Changes can reflect test conditions, natural variation, medications, or disease. |
| Post-Prostatectomy PSA Test | Very low levels of PSA after surgical removal of the prostate | Used for clinician-directed monitoring after prostatectomy | PSA is generally expected to fall substantially after surgery. Interpretation depends on the assay, timing, and treatment history. | Not intended for routine screening in people with an intact prostate. |
| Urinalysis Complete Test | Physical, chemical, and microscopic urine findings | May identify evidence of urinary inflammation, blood, or infection when urinary symptoms are present | White blood cells, nitrites, bacteria, or blood may require additional evaluation. | Does not determine whether a PSA elevation is caused by prostate cancer. |
| Culture, Urine, Routine Test | Bacterial or other microorganism growth in urine | May help evaluate a suspected urinary infection | Growth of a significant organism may support an infection diagnosis. | A negative culture does not rule out every cause of prostatitis or urinary symptoms. |
| Prostate Infection Panel | A combination of tests that may include PSA, blood counts, urinalysis, and urine culture-related testing | May provide broader information when prostate infection or inflammation is suspected | Results must be interpreted together with symptoms, medical history, and a clinical examination. | It is not a prostate cancer diagnostic panel. |
Some PSA circulates freely in the blood, while some is attached to proteins. The percent-free PSA is calculated by dividing free PSA by total PSA and multiplying by 100.
Percent-free PSA is most commonly considered when total PSA is within a borderline range, often approximately 4–10 ng/mL.
The American Cancer Society notes that percent-free PSA may help guide biopsy discussions when total PSA is between 4 and 10 ng/mL.
The PSA Total Test may be an appropriate starting point for someone who has made an informed decision to undergo prostate cancer screening or who needs clinician-directed PSA monitoring.
It should not be assumed that every adult male needs annual PSA testing.
A healthcare provider may consider:
The Urinalysis Complete Test, Culture, Urine, Routine Test, Complete Blood Count with Differential and Platelets, and other testing may be appropriate when fever, painful urination, pelvic discomfort, urgency, or other infection-related symptoms are present.
The Urinalysis Complete with Urine Culture Always combines a complete urinalysis with routine urine culture testing.
These tests investigate possible urinary or inflammatory causes. They are not substitutes for prostate cancer screening, medical evaluation, or diagnosis.
People who have undergone prostatectomy, radiation, hormone therapy, or another prostate cancer treatment require a monitoring plan established by their oncology or urology team. The Post-Prostatectomy PSA Test and other treatment-specific PSA assays may be interpreted differently from routine screening tests.
Your report will show the PSA result and the laboratory’s reference or decision range. This range should be treated as one piece of information, not as a diagnosis.
A stable result over time may be interpreted differently from a new increase. When possible, compare results from tests performed:
Before interpreting an elevated result, consider:
There is no universally accepted optimal PSA range for every age and risk group. A result can be inside a laboratory range and still deserve attention based on symptoms or personal risk. A result outside the range can have a benign explanation.
A rising PSA deserves attention, but the rate of increase should be evaluated with the absolute PSA level, age, health history, medication use, prostate size, and other clinical findings.
An isolated elevated result is sometimes repeated before secondary biomarkers, MRI, or biopsy are considered. Repeat timing should be individualized, particularly if temporary inflammation or recent prostate activity may have influenced the initial test.
Preparation requirements can vary, so always follow the instructions for the test ordered.
A discussion about PSA testing may be appropriate when you:
Having a risk factor does not automatically mean that you should undergo screening, and having no known risk factors does not guarantee that prostate disease will not occur.
Ulta Lab Tests allows patients to order many laboratory tests directly online where available. Prostate health testing options include the PSA Total Test, PSA Free and Total Test, and specialized monitoring tests.
Patients can review transparent pricing before ordering, and insurance is not required. Eligible HSA or FSA payment methods may be accepted. Specimen collection is performed through established laboratory networks such as Quest Diagnostics where applicable, and results are delivered through a secure online account.
Direct-access testing can make it easier to obtain objective health information and track results. However, Ulta Lab Tests does not replace a urologist or another qualified healthcare provider. Abnormal, changing, or unexpected PSA results should be professionally reviewed.
Explore related testing: Review prostate health blood tests and prostate cancer testing information from Ulta Lab Tests.
There is no PSA level that is universally normal for every person. A value below 4.0 ng/mL has historically been considered less concerning, but prostate cancer may occur below that level, and benign conditions may produce results above it. Age, prostate size, medications, family history, symptoms, and previous PSA results all affect interpretation.
No. High PSA levels can be caused by prostate cancer, but they can also result from benign prostate enlargement, prostatitis, urinary infection, ejaculation, cycling, or a recent prostate procedure. PSA identifies a reason to consider additional evaluation; it does not confirm cancer.
There is no single dangerous PSA level. Concern generally increases as PSA rises, particularly above 10 ng/mL, but even a substantially elevated result is not diagnostic. The appropriate response depends on whether the result is confirmed, symptoms, previous PSA levels, medications, age, family history, and other clinical findings.
Yes. A PSA below 4.0 ng/mL reduces concern in many situations but does not guarantee that prostate cancer is absent. Symptoms, abnormal examination findings, a strong family history, inherited risk, and changes from a person’s baseline may still justify clinical evaluation.
A newly elevated PSA is often repeated before more invasive evaluation, particularly when the person has no concerning symptoms. Repeat testing in approximately six to eight weeks may be recommended, although timing varies when infection, inflammation, recent procedures, or other temporary factors are present.
Total PSA includes PSA attached to blood proteins plus unbound, or free, PSA. The PSA Free and Total Test also calculates the percentage that is free. When total PSA is borderline, a lower percent-free PSA is generally associated with greater cancer concern, while a higher percentage may suggest a benign cause.
Yes. Ejaculation may temporarily increase PSA and make the result more difficult to interpret. Avoid sex or masturbation for at least 24 hours before testing. Some authorities recommend avoiding ejaculation and vigorous cycling for approximately 48 hours.
Fasting is generally not required when PSA is the only test ordered. However, fasting may be necessary when PSA is bundled with glucose, lipid, metabolic, or other tests. Review the preparation instructions for every test in your order.
Yes. Finasteride and dutasteride can lower measured PSA, sometimes substantially. Other medications and therapies may also influence results. Tell the healthcare provider interpreting the result about all medications and supplements, but do not stop anything unless instructed.
Ulta Lab Tests offers direct access to PSA testing where available. You can order online, complete the blood draw through the designated laboratory network, and access the results securely online. Direct ordering does not replace professional interpretation or follow-up for an abnormal result.
Testing frequency depends on age, initial PSA, family history, ancestry, general health, life expectancy, previous results, and personal preferences. Some guidelines recommend a longer screening interval when PSA is low and more frequent monitoring when PSA is higher. A healthcare provider can help determine an appropriate interval.
A provider may review medications and temporary influences, repeat the PSA test, perform a prostate examination, evaluate for infection, calculate prostate cancer risk, measure percent-free PSA, request imaging such as prostate MRI, or refer the patient to a urologist. A biopsy may be needed when tissue is required to determine whether cancer is present.
Understanding your PSA levels requires more than finding your number on a chart. PSA can provide important information about prostate activity, but it is influenced by age, benign prostate enlargement, inflammation, infection, medications, recent activities, and individual prostate cancer risk.
A high PSA is not a diagnosis, and a low PSA is not an absolute guarantee. The most informative approach combines accurate preparation, repeat testing when appropriate, comparison with previous results, individual risk assessment, and professional medical review.
Ulta Lab Tests offers convenient access to the PSA Total Test, PSA Free and Total Test, Post-Prostatectomy PSA Test, and related urinary testing. Explore the appropriate prostate health tests from Ulta Lab Tests and review your results with a qualified healthcare provider before making health or treatment decisions.
This article is provided for educational and informational purposes only. Laboratory testing does not diagnose prostate cancer or replace professional medical advice, examination, diagnosis, or treatment. Review abnormal, changing, or unexpected PSA results with a qualified healthcare provider.

Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)